Pharmafile Logo
Pharmafocus logo
Advanced Search

Amgen

Showing 15 posts of 214 posts found.

clinical_trial_4

Phase III study confirms similarity of Herceptin biosimilar from Amgen, Allergan

July 22, 2016
Medical Communications, Research and Development Allergan, Amgen, Herceptin, Roche, biosimilar, trastuzumab

Amgen and Allergan have announced the results from a Phase III study investigating ABP 980, their biosimilar candidate for Roche’s …

News
handshake

Amgen agrees deal to commercialise biosimilars in Japan with Daiichi Sankyo

July 14, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Amgen, Daiichi Sankyo, Japan, biosimilars

Amgen (NASDAQ: AMGN) has agreed a deal with Daiichi Sankyo (TSE: 4568) that will see the pair commercialise nine biosimilars …

News
fda_logo-web

US FDA committee recommends approval for Amgen’s biosimilar of AbbVie’s Humira

July 13, 2016
Research and Development, Sales and Marketing AbbVie, Amgen, Humira, US FDA, biosimilar, drug approval, drug trial, inflammatory diseases, rheumatoid arthritis

One of the world’s bestselling drug may soon have competition in the US markets after the regulators backed a biosimilar …

News
amgen_flag

FDA approves single monthly injection of Amgen’s Repatha

July 12, 2016
Manufacturing and Production, Sales and Marketing Amgen, FDA, Repatha, pushtronex

Amgen (NASDAQ: AMGN) has announced that the US Food and Drug Administration (FDA) has approved a new, monthly single-dose administration …

News
cancerstudy

Coherus BioSciences says Neulasta biosimilar shows positive topline results; shares jump

July 12, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Amgen, Cancer, Coherus BioSciences, biosimilar, drug trial

Shares in Coherus BioSciences (Nasdaq: CHRS) jumped to close over 27% after the company said its biosimilar copy for Amgen’s …

News
amgen_hq

Amgen’s Humira biosimilar candidate “highly similar” to originator, says FDA

July 8, 2016
Research and Development, Sales and Marketing ABP-501, AbbVie, Amgen, FDA, Humira, abp 501, biosimilar

A report from a meeting of the US Food and Drug Administration’s (FDA) Arthritis Advisory Committee has concluded that Amgen’s …

News
pfizer_enbrel

New data shows Sandoz’s Enbrel biosimilar has equivalent efficacy profile

July 7, 2016
Research and Development, Sales and Marketing Amgen, EMA, Enbrel, FDA, Novartis, Sandoz, biosimilars

Sandoz has announced new data confirming the equivalent safety and efficacy profile of their biosimilar version of Enbrel (etanercept) in …

News
amgen_hq

Amgen says its blood cancer drug gets European backing for extended indication

July 4, 2016
Research and Development, Sales and Marketing Amgen, European Commission, Kyprolis, blood cancer, drug trial

Amgen (Nasdaq: AMGN) said the European Commission (EC) has approved a variation to the marketing authorization for its Kyprolis (carfilzomib) to include use …

News
takeda_world

Takeda to return molecules/ products for Japan to Amgen

June 27, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Amgen, Cancer, Japan, Takeda Pharmaceutical, drug development, drug trial

Japanese firm Takeda Pharmaceutical (TSE: 4502) said it will return the rights to develop and market multiple molecules/ products from …

News

Nice backs two cancer drugs from Novartis

June 22, 2016
Research and Development, Sales and Marketing AbbVie, Amgen, Humira, NICE, Novartis, Sanofi, lung cancer, skin cancer

The National Institute for Health and Care Excellence (Nice) has backed two drugs form Novartis (VTX: NOVN) for lung cancer …

News
amgen_flag

Amgen’s denosumab may help check breast cancer in women with BRCA1 gene – Study

June 21, 2016
Manufacturing and Production, Research and Development Amgen, Prolia, Xgeva, biotech, breast cancer, drug trial, genetics

US biotech firm Amgen’s (Nasdaq: AMGN) Prolia (denosumab) to treat osteoporosis and Xgeva to prevent fractures in cancer patients, may …

News
amgen_flag

FDA to review data on Amgen’s Humira biosimilar

June 14, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Amgen, FDA, Humira, biosimilar

Amgen (NASDAQ: AMGN) has announced the US Food and Drug Administration’s (FDA) Arthritis Advisory Committee will review data supporting the …

News

Amgen, Novartis migraine drug meets primary endpoint in Phase II study

June 9, 2016
Research and Development AMG 334, Amgen, Novartis, Phase II, chronic, erenumab, migraine

A new treatment for chronic migraine prevention, co-developed by Novartis (NYSE: NVS) and Amgen (NASDAQ: AMGN), showed a statistically significant …

News
amgen_flag

Amgen showcases positive Phase III multiple myeloma drug at ASCO

June 7, 2016
Manufacturing and Production, Research and Development ASCO, Amgen, Kyprolis, dexamethasone, lenalidomide, multiple myeloma

Amgen (NASDAQ: AMGN) has presented data showing a statistically significant increase in progression-free survival and overall response rate in multiple …

News
medivation

Medivation maybe mulling sale as bidding race heats up – Reports

May 10, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Amgen, Deals, M&A, MA, Medivation, Pfizer, Sanofi

Cancer drugmaker Medivation (Nasdaq: MDVN) is evaluating a potential sale following the recent string of offers from big pharma firms, …

News

Latest content

GSK shares data from global shingles survey

December 1, 2023

AbbVie to acquire ImmunoGen for approximately $10.1bn

December 1, 2023

FDA accepts NDA for Karuna’s schizophrenia treatment

November 30, 2023

Vivos Therapeutics gains FDA 510(k) clearance for sleep apnea treatment device

November 30, 2023

Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance

November 29, 2023